UBS has given GSK a 'Neutral' rating and set a target price of 1580 pence before the release of the company's third-quarter results.
Analyst Jo Walton has expressed concerns about the performance of GSK's vaccination business, specifically the Shingrix and Arexvy vaccines, which are expected to struggle in the U.S. market.
The uncertain outlook for GSK's vaccination segment raises questions about the company's prospects for the upcoming year. Investors will closely watch the third-quarter figures to assess the impact of these developments on GSK's overall performance.